Contract facts
NONENo full NAICS 325412 intel page yet. Browse NAICS intelligence
GSK TRAVEL VACCINES is a federal NONE award for Division 1200 held by Glaxosmithkline LLC. Estimated value $115K ($50K obligated). Current period of performance ends Dec 31, 2024 (potential Dec 31, 2026). Last award drew 1 bidder. Place of performance: DURHAM NC.
Recompete timing
PublicCurrent PoP ended Dec 31, 2024 (598 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordGlaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 15F06724F0001366?
15F06724F0001366 (GSK TRAVEL vaccines) is a Division 1200 award with a potential value of $115K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 15F06724F0001366?
Division 1200 awarded 15F06724F0001366 to Glaxosmithkline LLC (potential $115K).
Who is the incumbent on 15F06724F0001366?
Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2024.
When does Glaxosmithkline LLC’s 15F06724F0001366 come up for recompete?
SCOUT tracks a period-of-performance end of Dec 31, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.